Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US

THOUSAND OAKS, Calif. and BRUSSELS, July 16, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for... Biopharmaceuticals, FDA Amgen, UCB, EVENITY, romosozumab, osteoporosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news